Business Wire (press release)Lysosomal Storage Diseases Market to Witness Growth with the Emergence of Immunotherapy | TechnavioBusiness Wire (press release)The properties of the immune system to fight abnormal cells give immunotherapies a chance to su… Continue reading
Cancer Therapy AdvisorctDNA Sequencing Predicts Likelihood of Immunotherapy ResponseCancer Therapy AdvisorMutations in circulating tumor DNA (ctDNA) may indicate which patients are likely to respond to checkpoint inhibition, according to research publi… Continue reading
Cancer Therapy AdvisorctDNA Sequencing Predicts Likelihood of Immunotherapy ResponseCancer Therapy AdvisorMutations in circulating tumor DNA (ctDNA) may indicate which patients are likely to respond to checkpoint inhibition, according to research publi… Continue reading
Labiotech.eu (blog) |
CRISPR Gets Snubbed Again by the Nobel Prize Committee
Labiotech.eu (blog) The Nobel Prize Committee has made CRISPR wait at least one more year, as it was pipped by research into the mechanisms underlying circadian rhythm. The 2017 Nobel Prize in Physiology or Medicine has been awarded to Jeffrey C. Hall, Michael … Nobel Prize 2017: Free Beer, Free Parking and Other Perks Winners Can ExpectNewsweek Here’s How The Body Keeps Time, Thanks to This Year’s Nobel Winning ScienceGizmodo Nobel 2017 season opens with medicine prizeDigital Journal |
Myeloma Research News |
Patient Recruitment Begins for Phase 1 Trial of P-BCMA-101 CAR T-Cell Therapy for Multiple Myeloma
Myeloma Research News A Phase 1 trial sponsored by Poseida Therapeutics for the company’s investigational CAR T-cell therapy for multiple myeloma, P-BCMA-101, is now enrolling participants. The potential therapy specifically targets a molecule found on the surface of … |
Myeloma Research News |
Patient Recruitment Begins for Phase 1 Trial of P-BCMA-101 CAR T-Cell Therapy for Multiple Myeloma
Myeloma Research News A Phase 1 trial sponsored by Poseida Therapeutics for the company’s investigational CAR T-cell therapy for multiple myeloma, P-BCMA-101, is now enrolling participants. The potential therapy specifically targets a molecule found on the surface of … |
Myeloma Research News |
Patient Recruitment Begins for Phase 1 Trial of P-BCMA-101 CAR T-Cell Therapy for Multiple Myeloma
Myeloma Research News A Phase 1 trial sponsored by Poseida Therapeutics for the company’s investigational CAR T-cell therapy for multiple myeloma, P-BCMA-101, is now enrolling participants. The potential therapy specifically targets a molecule found on the surface of … |
|
Asterias Bio’s stem cell therapy shows encouraging long-term effect in Phase 1/2 study in spinal cord injury …
Seeking Alpha Asterias Biotherapeutics (AST +2.7%) announces positive results from the Phase 1/2 SCiStar study assessing AST-OPC1 in patients with subacute motor complete spinal cord injury. Results at month 12 showed 67% of those with AIS-A-categorized injury … |